Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atomo Diagnostics Ltd. ( (AU:AT1) ) has shared an announcement.
Atomo Diagnostics Ltd. has applied for quotation on the ASX of 90,909,091 new ordinary fully paid shares under its existing ticker AT1. The securities are to be issued and quoted on 8 April 2026, expanding the company’s listed share capital and potentially increasing its market liquidity.
The application follows previously announced transactions, indicating these new shares form part of an earlier approved capital issuance. The enlarged register may support Atomo Diagnostics’ funding capacity for its diagnostics operations, with implications for existing shareholders through dilution and for the company’s positioning in public capital markets.
The most recent analyst rating on (AU:AT1) stock is a Hold with a A$0.03 price target. To see the full list of analyst forecasts on Atomo Diagnostics Ltd. stock, see the AU:AT1 Stock Forecast page.
More about Atomo Diagnostics Ltd.
Atomo Diagnostics Ltd. is an Australian-listed healthcare company focused on diagnostics, with its ordinary fully paid shares traded on the ASX under the ticker AT1. The company operates in the medical diagnostics industry, developing and commercialising testing solutions for health applications.
Average Trading Volume: 2,045,256
Technical Sentiment Signal: Sell
Current Market Cap: A$25.93M
Learn more about AT1 stock on TipRanks’ Stock Analysis page.